In vivo neutralization of anti-A and successful transfusion of A antigen-incompatible red blood cells in an animal model

Transfusion

Volumn 51, Issue 12, 2011, Pages 2664-2675

  Oliver, Caroline ^a   Blake, Deborah ^a   Henry, Stephen ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; BLOOD GROUP A ANTIBODY; BLOOD GROUP A ANTIGEN; GLYCOLIPID; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GROUP A; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN;

EID: 83555172219     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03184.x     Document Type: Article

References (43)

1. Janatpour KA, Kalmin ND, Jensen HM, Holland PV,. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol 2008; 129: 276-81. (Pubitemid 352029318)
2. Mollison PL,. The transfusion of red cells. In:, Klein HG, Anstee DJ, editors. Mollison's blood transfusion in clinical medicine. 11th ed. Oxford: Blackwell Scientific Publications; 2005. p. 412-75.
3. Chaplin H,. Studies on the survival of incompatible cells in patients with hypogammaglobulinaemia. Blood 1959; 14: 24-36.
4. Zimring JC, Hair GA, Chadwick TE, Deshpande SS, Anderson KM, Hillyer CD, Roback JD,. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood 2005; 106: 1105-12. (Pubitemid 41076461)
5. Zimring JC, Caldwell CM, Spitalnik SL,. Antigen loss from antibody-coated red blood cells. Transfus Med Rev 2009; 23: 189-204.
6. Liepkalns JS, Zimring JC,. Crossmatch incompatible RBCs have an intrinsic range of susceptibility to hemolysis. Transfusion 2009; 49: 28A.
7. Nussbaumer W, Schwaighofer H, Gratwohl A, Kilga S, Schönitzer D, Nachbaur D, Niederwieser D,. Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility. Transfusion 1995; 35: 592-5.
8. Scholl S, Klink A, Mügge LO, Schilling K, Höffken K, Sayer HG,. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion 2005; 45: 1676-83.
9. Olsson ML, Clausen H,. Modifying the red cell surface: towards an ABO-universal blood supply. Br J Haematol 2007; 140: 3-12.
10. Garratty G,. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang 2008; 94: 87-95.
11. Crew RJ, Ratner LE,. ABO-incompatible kidney transfusion:current practice and the decade ahead. Curr Opin Org Transplant 2010; 15: 526-30.
12. Mollison PL, Polley MJ, Crome P,. Temporary suppression of Lewis blood-group antibodies to permit incompatible transfusion. Lancet 1963; 1: 909-12.
13. Pelosi MA, Bauer JL, Langer A, Hung CT,. Transfusion of incompatible blood after neutralization of Lewis antibodies. Obstet Gynaecol 1974; 44: 590-3.
14. Frame T, Carroll T, Korchagina E, Bovin N, Henry S,. Synthetic glycolipid modification of red blood cell membranes. Transfusion 2007; 47: 876-82. (Pubitemid 46669002)
15. Heathcote D, Carroll T, Wang JJ, Flower R, Rodionov I, Tuzikov A, Bovin N, Henry S,. Novel antibody screening cells, MUT+Mur kodecytes, created by attaching peptides onto red blood cells. Transfusion 2010; 50: 635-41.
16. Harrison AL, Olsson ML, Jones RB, Ramkumar S, Sakac D, Binnington B, Henry S, Lingwood CA, Branch DR,. A synthetic globotriaosylceramide analogue inhibits HIV-1 infection in vitro by two mechanisms. Glycoconj J 2010; 27: 515-24.
17. Oliver C, Blake D, Henry S,. Modeling transfusion reactions and predicting in vivo cell survival with kodecytes. Transfusion 2011; 51: 1723-30.
18. Barr K, Diegel O, Parker S, Bovin N, Henry S,. Function-Spacer-Lipid (FSL) constructs enable inkjet printing of blood group antigens [abstract E1.12]. FEBS J 2010; 277 Suppl 1: 235.
19. Hoff J,. Methods of blood collection in the mouse. Lab Anim 2000; 29: 47-53.
20. Rydberg L,. ABO-incompatiblity in solid organ transfusion. Transfus Med 2001; 11: 325-42.
21. Lefebre J, McLellan BA, Coovadia AS,. Seven years experience with group O unmatched packed red blood cells in a regional trauma unit. Ann Emerg Med 1987; 16: 1344-8.
22. British Committee for Standards in Haematology, Blood Transfusion Task Force (Chairman P Kelsey). Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
23. Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K,. ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion 2009; 49: 2442-53.
24. Cooper DK, Ye Y, Niekrasz M, Kehoe M, Martin M, Neethling FA, Kosanke S, DeBault LE, Worsley G, Zudhi N, Oriol R, Romano E,. Specific intravenous carbohydrate therapy. A new concept in inhibiting antibody-mediated rejection-experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993; 56: 769-77. (Pubitemid 23321503)
25. Romano EL, Soyano A, Montano RF, Ratcliffe M, Olson M, Suarez G, Martinez N, Worsely G,. Treatment of ABO hemolytic disease with synthetic blood group trisaccharides. Vox Sang 1994; 66: 194-9. (Pubitemid 24103655)
26. b-active glycolipid in serum of pregnant women. Vox Sang 1981; 40: 27-33. (Pubitemid 11136631)
27. b-active glycolipid in human plasma: measurement by radioimmunoassay. Arch Biochem Biophys 1980; 199: 265-9. (Pubitemid 10151619)
28. Swarzmann G,. Uptake and metabolism of exogenous glycosphingolipids by cultured cells. Cell Dev Biol 2001; 12: 163-71.
29. Larkin JM, Porter CD,. Mice are unsuitable for modeling ABO discordance despite strain-specific A cross reactive natural IgM. Br J Haematol 2005; 130: 310-7. (Pubitemid 41602533)
30. Néron S, Lemieux R,. Type 2 T-cell-independent murine immune response to the human ABO blood group antigens. Vox Sang 1994; 67: 68-74. (Pubitemid 24206508)
31. Galili U,. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplant 2004; 78: 1093-8. (Pubitemid 39426422)
32. Oriol R, Le Pendu J, Mollicone R,. Genetics of ABO, H, Lewis, X and related antigens. Vox Sang 1986; 51: 161-71. (Pubitemid 17197721)
33. Hod EA, Zimring JC, Spitalnik SL,. Lessons learned from mouse models of hemolytic transfusion reactions. Curr Opin Haematol 2008; 15: 601-5.
34. Marcus DM, Cass LE,. Glycosphingolipids with Lewis blood group activity: uptake by human erythrocytes. Science 1969; 164: 553-5.
35. Sneath JS, Sneath PH,. Transformation of the Lewis groups of human red cells. Nature 1955; 176: 172.
36. 13C MRS examinations of the brain. Magn Reson Med 2001; 46: 39-48. (Pubitemid 32592137)
37. Josephson DL,. Intravenous nutritional support. In:, Josephson DL, editor. Intravenous infusion therapy for nurses. 2nd ed. Clifton Park (NY): Thomson Delmar Learning; 2004. p. 399.
38. Romano EL, Soyano A, Linares J, Lauzon GJ,. Neutralization of ABO blood group antibodies by specific oligosaccharides. Transplant Proc 1987; 19: 4426-30. (Pubitemid 18049632)
39. Andorka DW, Arosemena A, Harris JL,. Neutralization in vivo of Lewis antibodies. Report of two cases. Am J Clin Pathol 1974; 62: 47-51.
40. De Libero G,. The Robin Hood of antigen presentation. Science 2004; 303: 485-7. (Pubitemid 38120839)
41. Lingwood CA, Murray RK, Schachter H,. The preparation of rabbit antiserum specific for mammalian testicular sulfogalactoglycerolipid. J Immunol 1980; 124: 769-74. (Pubitemid 10135319)
42. Alving CR, Richards RL,. Immune reactivities of antibodies against glycolipids-II. Comparative properties, using liposomes, of purified antibodies against mono-, di and trihexosyl ceramide haptens. Immunochemistry 1977; 14: 383-9. (Pubitemid 8133296)
43. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Ritter G, Fersht AR, Besra GS, Schmidt RR, Jones EY, Cerundolo V,. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 2005; 6: 819-26. (Pubitemid 43090468)